After You Return

Medicine & Health Care Summit at Johns Hopkins — Ambassador Leaders

After You Return | Johns Hopkins Medicine

Arrive on Johns Hopkins University campus and check in to the Summit. After saying good-byes, parents can attend an optional brief orientation, while students join their peers for icebreakers.

Enjoy the welcome dinner and opening address, and get to know your teacher leaders and staff who will guide you during the Summit.

Meet your group and get to know your teammates as you review the exciting week ahead.

DAY 2: CHALLENGE YOURSELF

Push your limits during a hands-on team building experience at a high ropes course. Build trust with your team as you problem-solve and overcome obstacles together.

Receive an introduction to intriguing patient case studies that you and your teammates will examine during the Summit.

Following your dreams takes persistence and grit. Fuel your passion when you hear from a keynote speaker –an accomplished physician or a public health expert.

DAY 3: cHART YOUR COURSE TO A MEDICAL SCHOOL

Hear about Hopkins’ academic community, student life and application process directly from a JHU Admissions counselor, then explore JHU campus during a tour led by JHU students.

Visit University of Maryland Medical School and its state-of-the-art research facilities. Hear from a panel of medical students and take part in a hands-on simulation experience in the Shock Trauma Advanced Medical Simulation Lab.

Then, learn crucial life-saving skills during the Stop The Bleed training and certification.

Discuss leadership in the field of medicine with your peers and examine its implications for your future career.

DAY 4: MEET THE EXPERTS

Participate in a patient interviewing and examination workshop and learn important patient care skills.

Dive into your case studies with your team. Hone your new skills by examining patient symptoms and learning what to look for to narrow down the diagnosis.

Meet a panel of medical professionals and hear about different career paths you can take in the medical field, and the challenges and rewards of each.

Take part in a Medical Ethics Committee discussion and address hot topics such as gene therapy, stem cell research, and others.

DAY 5: eXPLORE WASHINGTON, dc

Learn about past and present leaders during an action-packed day in Washington, DC. Start the day with an enlightening tour of the US Capitol Building and examine the history and present day of our country’s government.

Explore the National Mall and pay tribute at the awe-inspiring national monuments and memorials.

Back on campus, continue working with your team on your case study research and presentation.

DAY 6: Get hands-on with medicine

Roll up your sleeves during a CPR training and earn your CPR/AED certification from the American Red Cross.

Learn technical suturing skills working with a surgeon and put your skills into practice during a suturing simulation.

Take part in an interactive workshop to learn about reflexes, cranial nerves and vital signs.

Hear from a panel of JHU students about college life and how you can prepare for medical education.

DAY 7: Make an impact

Give back to the local communities in Baltimore through a hands-on service project with United Way. Examine how you can make community service an essential part of preparing for your career in the medical field.

Visit the National Institutes of Health (NIH), one of the world’s foremost medical research centers, and learn about careers addressing the growing global health challenges.

Explore the renowned National Museum of Health & Medicine and learn about the history and practice of American medicine.

DAY 8: Unveil your case study

It’s your time to shine! Present your case-study conclusions to your peers and get feedback.

Celebrate your accomplishments in style and bond with your friends during a banquette and dance cruise on the Baltimore Harbor.

Explore Baltimore’s vibrant Inner Harbor and shop for mementos to remember your time in Baltimore.

DAY 9: Serve with passion!

In the morning, bid farewell to your friends and teacher leaders. Believe in yourself and remember to lead through service as you go after your dreams in medicine.

This is a sample itinerary of what students may experience on program. Events, speakers and site visits are subject to confirmation and change.

Notice: This program is developed and operated solely by Ambassador Leaders. Ambassador Leaders has leased or rented facilities from the Johns Hopkins University.

Ambassador Leaders and any of its programs are not related to or affiliated with the Johns Hopkins University.

Ambassador Leaders is a separate legal entity with no connection to the Johns Hopkins University aside from the use of facilities for the specified program.

Source: https://ambassadorleaders.com/medicine

Employee & Student Parking Rates

After You Return | Johns Hopkins Medicine

The following information is for the East Baltimore campus only. If you’re a Bayview employee, see the Guide to Parking Services at Bayview.

On-campus garages and lots
Satellite parking lots
Hourly rates
Free employee & student parking
Departmental Parking Coupons

Monthly rates for on-site garages and lots

On-campus garages – $120.00Church Home garage – $105.00Satellite parking lots – $50.00

Evening shift (after 1:00 p.m.) – $70.00

Monthly rates for satellite parking lots

Monument Street and *Fallsway lots – $50.00

*A $20.00 refundable deposit is required at sign-up for the Fallsway lot.

Note: The Monument Lot transient rate for non-permit holders is a flat rate of $5 per day.

Hourly rates (Garages)

The following rates will apply if you have no parking permit and are parking during peak (non-base access) hours:

$4.00 ………………. Up to 1 hour$5.00 ………………. Up to 3 hours$6.00 ………………. Up to 4 hours$7.00 ………………. Up to 5 hours$8.00 ………………. Up to 6 hours

$13.00 …………….. Maximum for 24 hours

Free employee & student parking

Employees and students may park for free on the East Baltimore campus during “Base Access” time periods:

Monday – Friday, *3:00 p.m. – 10:00 a.m.
All day Saturday, Sunday and designated holidays

*NOTE:  Temporary COVID-19 Time Frame until further notice.  The Base Access/free parking time period will revert back to 4:00 p.m. – 8:30 a.m. on weekdays when this temporary measure is lifted.  

Your JHMI I.D. badge is your “parking permit” during these time periods. You must register your ID Badge with the Parking Office to enable Base Access swipe privileges.  You will be required to swipe your badge to access and exit all JHMI campus parking facilities (excluding the 550 Lot and the Weinberg Garage). 

NOTE: Please be advised that employees/students who pull tickets during Base Access time periods instead of swiping their ID Badge will be charged regular transient rates. Please be sure to register your ID Badge with the Parking Office to avoid incurring hourly garage fees during the Base Access time periods.

If you swipe your card and the system fails to grant you access, please do the following:

  1. Make sure you are swiping your card correctly. The black magnetic stripe should be facing the arrow on the card reader.
  2. Try swiping your card in both directions several times.
  3. If you have tried steps 1 and 2, and are getting a red light or no light change when you swipe, press the intercom button for assistance.
  4. You also can reach the Parking Office at 5-5333 or 5-8803, or the I.D. Office at 5-5325, Monday – Friday, 8:00 a.m. – 4:00 p.m. After office hours, please leave a voicemail message with the following information:
    • Your Name (please spell your name clearly)
    • Card Number (the number should be printed on your I.D. badge)
    • Clearly describe the problem you are experiencing (i.e., you are getting a Red light when you swipe, or there is no change in lights when you swipe, etc.).
    • The hours you work and a phone number where you can be reached.

For a walking security escort to/from garages, call 410-955-5585, 24 hours, 7 days. Learn more about escort services.

Departmental Parking Coupons

Books of departmental parking coupons are available for purchase by authorized departments, and can be given to patients and visitors in accordance to guidelines.

Only authorized departments and individuals may purchase departmental parking coupons.

Departmental parking coupons are for patients, visitors and seminar participants only and are not to be used by faculty, students or staff.*

A book of 10 stamps is $120.00.

For more information, please contact the Parking Office at 410-955-5333 or view guidelines on where and how to purchase.

*JHH Internal Audit recommends that we randomly verify users of departmental coupons and/or validations. Any abuse of departmental coupons or validations may result in termination from the program and/or notification to the department head for disciplinary action.

Source: https://intranet.insidehopkinsmedicine.org/security_parking/parking/rates.html

COVID-19: School of Public Health Expert Insights – Johns Hopkins Bloomberg School of Public Health

After You Return | Johns Hopkins Medicine

Allison Barlow and Laura Hammitt co-authored the op-ed.  

Researchers from Johns Hopkins say contact tracing crucial for safely reopening states

Emily Gurley and Crystal Watson are mentioned. 

Baltimore should close some streets for walking, biking during pandemic

Keshia Pollack Porter and MPH student Eli Pousson co-wrote the Op-Ed.

Here's How You Can Change Lives in a Pandemic

The Center for American Indian Health was one of five organizations chosen to be part of “Nick Kristof's C-9 Impact Initiative”

The success of a COVID-19 vaccine will hinge on its delivery

Lois Privor-Dumm, Naor Bar-Zeev, and Maria Deloria Knoll wrote the article.

Source: https://www.jhsph.edu/covid-19/

Johns Hopkins Scientists Give Psychedelics the Serious Treatment

After You Return | Johns Hopkins Medicine

Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look.

Scientists are rediscovering what many see as the substances’ astonishing therapeutic potential for a vast range of issues, from depression to drug addiction and acceptance of mortality. A frenzy of interest has captivated a new generation of researchers, aficionados and investors, triggering some understandable wariness over promises that may sound a little too good to be true.

But late last year the highly respected institution Johns Hopkins University—the U.S.’s oldest research university—launched a dedicated center for psychedelic studies, the first of its kind in the country and perhaps the world’s largest.

With work now underway, the center is aiming to enforce the strictest standards of scientific rigor on a field that many feel has veered uncomfortably close to mysticism and that has relied heavily on subjective reports. Early results have been promising and seem poised to keep the research on a roll.

Psilocybin (a psychoactive compound found in certain mushrooms) and LSD were widely studied in the 1950s and 1960s as treatments for alcoholism and other maladies.

They later gained a reputation in the media and the public eye as dangerous and became strongly associated with the counterculture. Starting in 1966, several states banned their use.

In 1968 LSD was outlawed nationwide, and in 1970 Congress passed the Controlled Substances Act, classifying that drug and psilocybin, along with several others, as having a high potential for abuse and no accepted medical use.

But in recent years a rapidly growing number of studies reporting encouraging results in treating depression, addiction and post-traumatic stress disorder (PTSD) have brought them back the shadows, spurred on by positive media coverage.

In a major boost to the reviving field, Johns Hopkins’s Center for Psychedelic and Consciousness Research is exploring the use of psychedelics—primarily psilocybin—for problems ranging from smoking addiction to anorexia and Alzheimer’s disease.

“One of the remarkably interesting features of working with psychedelics is they’re ly to have transdiagnostic applicability,” says Roland Griffiths, who heads the new facility and has led some of the most promising studies evaluating psilocybin for treating depression and alcoholism.

The myriad applications suggested for these drugs may be a big part of what makes them sound, to many, snake oil—but “the data [are] very compelling,” Griffiths says. And psychedelics may not only hold hope for treating mental disorders.

As Griffiths puts it, they provide an opportunity to “peer into the basic neuroscience of how these drugs affect brain activity and worldview in a way that is ultimately very healthy.”

As author Michael Pollan chronicles in his 2018 best seller How to Change Your Mind, researchers were examining the therapeutic effects of psychedelics in the 1950s—a decade before then Harvard University psychologist Timothy Leary and his colleague Richard Alpert started their notorious study in which they gave psilocybin to students (ultimately leading to Leary’s and Alpert’s dismissal from the university). In the 1950s–1970s, studies conducted with LSD—which acts on the same brain receptors as psilocybin—reported strong results in treating substance use disorders, including alcohol and heroin addiction. But when LSD became illegal in 1968, funding for this work gradually dried up. Most psychedelics research stopped or went underground.

Psychedelics’ New Wave

Griffiths and some of his colleagues helped revive the field around 2000, when they obtained government approval to give high doses of psilocybin to healthy volunteers. The researchers published a foundational study in 2006 showing a single dose was safe and could cause sustained positive effects and even “mystical experiences.

” A decade later they published a randomized double-blind study showing psilocybin significantly decreased depression and anxiety in patients with life-threatening cancer. Each participant underwent two sessions (a high-dose one and a low-dose one) five weeks apart.

Six months afterward, about 80 percent of the patients were still less clinically depressed and anxious than before the treatment. Some even said they had lost their fear of death.

Armed with these promising results, Griffiths and his colleagues turned their attention to other clinical applications.

They decided to investigate tobacco addiction—in part because it is much easier to quantify than emotional or spiritual outcomes.

Johns Hopkins researcher Matthew Johnson led a small pilot study in 2014 to see whether psilocybin could help people quit smoking. It was an open-label study, meaning the participants knew they were getting the drug and not a placebo.

The work followed a classic model for psychedelic therapy in which the participant lies on a couch and wears eyeshades while listening to music.

Researchers do not talk to or guide subjects during the trip, but before each session, they do try to prepare people for what they might experience.

In Johnson and his colleagues’ study, participants also underwent several weeks of cognitive-behavioral therapy (talk therapy aimed at changing patterns of thinking) before and after taking psilocybin.

The drug was given in up to three sessions—one on the target quit date, another two weeks later and a third, optional one eight weeks afterward. The subjects returned to the lab for the next 10 weeks to have their breath and urine tested for evidence of smoking and came back for follow-up meetings six and 12 months after their target quit date.

At the six-month mark, 80 percent of smokers in the pilot study (12 15) had abstained from cigarettes for at least a week, as verified by Breathalyzer and urine analysis—a vast improvement over other smoking cessation therapies, whose efficacy rates are typically less than 35 percent.

In a follow-up paper, Johnson and his colleagues reported that 67 percent of participants were still abstinent 12 months after their quit date, and 60 percent of them had not smoked after 16 months or more.

Additionally, more than 85 percent of the subjects rated their psilocybin trip as one of the five most meaningful and spiritually significant experiences of their lives.

The team is currently more than halfway through a larger, five-year study of 80 people randomized to receive either psilocybin or a nicotine patch at the new Johns Hopkins center. Recruitment for the study is ongoing.

The exact brain mechanism by which the therapy appears to work remains unclear. At the psychological level, Johnson says, there is evidence that the sense of unity and mystical significance many people experience on psilocybin is associated with greater success in quitting, and those who take the drug may be better able to deal with cravings.

At the biological level, he adds, scientists have hypothesized that psilocybin may alter communication in brain networks, possibly providing more top-down control over the organ’s reward system.

A team led by Johns Hopkins cognitive neuroscientist Frederick Barrett is now investigating further by using functional magnetic resonance imaging to measure brain activity before and after patients undergo the therapy.

any drug, psilocybin comes with risks. People with psychotic disorders such as schizophrenia (or a strong predisposition for them) are generally advised against taking the hallucinogen.

People with uncontrolled hypertension are advised to abstain as well, because psilocybin is known to raise blood pressure.

Although it appears to be one of the safest “recreational” drugs and is not considered addictive, there have been reports associating it with deaths—but these may have been the result of multiple drugs, impure substances or underlying medical issues.

In the smoking study, a third of participants experienced some fear or anxiety at a high dose of the psilocybin, Johnson says. But he adds that the risks can be minimized by carefully selecting participants and administering the drug in a controlled environment.

The smoking study results are promising, but Johnson says its relatively small size is a limitation. Also, subjects in such studies cannot comprise a completely random sample of the population, because it would be unethical to recruit people without telling them they may be taking a psychedelic drug.

Thus, participants tend to be people who are open to this category of experience and, potentially, more apt to believe in its efficacy. And it is also hard to tease apart the effects of psilocybin from those of the cognitive-behavioral therapy in the smoking study, Johnson notes.

He and his colleagues at the new center plan to conduct a double-blind, placebo-controlled study—the gold standard for medical investigations—in the future.

Johns Hopkins researchers are also starting or planning studies using psilocybin therapy for a wide range of other conditions, including opioid addiction, PTSD, anorexia, post-treatment Lyme disease syndrome, Alzheimer’s disease and alcoholism in people with depression.

David Nichols, a professor emeritus of pharmacology at Purdue University, who was not involved in the recent Johns Hopkins studies but had synthesized the psilocybin used in Griffiths’s 2006 and 2016 papers, has been conducting research on psychedelics since the late 1960s.

Back then, “you probably could have counted on one hand the number of people in the world that were working in this field. There wasn’t any money; there was no interest. [Psychedelics] were just looked at as drugs of abuse,” he says.

Now “there’s a whole society set up to study these, with probably 150 international scientists working on it.”

Nichols says he has supported Griffiths’s and Johnson’s work since its early days, as they gathered the initial data that excited wealthy donors enough to fund the latest research.

Philanthropic funding “is the way it’s going to be—until the National Institutes of Health decide that this is a field worth funding,” he says.

“There are still too many political considerations that are keeping that from happening, but eventually, we’ll get there. We’ll get institutional support. We’re just not there yet.”

Source: https://www.scientificamerican.com/article/johns-hopkins-scientists-give-psychedelics-the-serious-treatment/